Posts filed under ‘GUIDELINES’
Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study
PLOS Medicine December 29, 2015
Courtney M. Yuen, Ekaterina V. Kurbatova, Thelma Tupasi, Janice Campos Caoili, Martie Van Der Walt, Charlotte Kvasnovsky, Martin Yagui, Jaime Bayona, Carmen Contreras, Vaira Leimane, Julia Ershova, Laura E. Via, HeeJin Kim
World Health Organization (WHO) guidelines for the treatment of multidrug-resistant tuberculosis (MDR TB) recommend a regimen consisting of at least four second-line drugs that are likely to be effective as well as pyrazinamide . In the absence of drug susceptibility testing (DST) results for a patient’s isolate, likely effectiveness is determined based on previous exposure to a drug, background resistance levels to that drug in the community, and, in patients who were contacts to other known cases, DST results for an associated case. Furthermore, the guidelines indicate that only marginal benefit has been observed for regimens based directly on the DST results for a patient’s isolate .
A meta-analysis of cohort studies of patients with MDR TB reported that in vitro susceptibility to individual drugs was consistently and statistically significantly associated with higher odds of treatment success compared to in vitro resistance, suggesting clinical utility for DST in regimen design . In addition, the use of baseline DST results to design individualized regimens involving prolonged use of five or more drugs with likely effectiveness has been associated with decreased risks of treatment failure, death, and relapse among patient cohorts in Peru and the Russian Federation [3–5]. Together, this evidence suggests the need to reassess both the role of DST in regimen design as well as the potential benefit of including more drugs in MDR TB regimens….
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2016
MMWR Morb Mortal Wkly Rep 2016;65:88–90
David K. Kim, MD; Carolyn B. Bridges, MD; Kathleen H. Harriman, PhD; et al.
In October 2015, the Advisory Committee on Immunization Practices (ACIP)* approved the Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2016. This schedule provides a summary of ACIP recommendations for the use of vaccines routinely recommended for adults aged 19 years or older in two figures, footnotes for each vaccine, and a table that describes primary contraindications and precautions for commonly used vaccines for adults. Although the figures in the adult immunization schedule illustrate recommended vaccinations that begin at age 19 years, the footnotes contain information on vaccines that are recommended for adults that may begin at age younger than age 19 years. The footnotes also contain vaccine dosing, intervals between doses, and other important information and should be read with the figures.
Advisory Committee on Immunization Practices Recommended Immunization Schedules for Persons Aged 0 Through 18 Years — United States, 2016
MMWR Morb Mortal Wkly Rep 2016;65:86–7
Candice L. Robinson, MD; Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group.
Each year, the Advisory Committee on Immunization Practices (ACIP)* reviews the recommended immunization schedules for persons aged 0 through 18 years to ensure that the schedules reflect current recommendations for Food and Drug Administration-licensed vaccines. In October 2015, ACIP approved the recommended immunization schedules for persons aged 0 through 18 years for 2016; the 2016 schedules include several changes from the 2015 immunization schedules. For 2016, the figures, footnotes, and tables will be published on the CDC immunization schedule website (http://www.cdc.gov/vaccines/schedules/index.html). This provides readers electronic access to the most current version of the schedules and footnotes on the CDC website. Health care providers are advised to use figures, tables, and the combined footnotes together. Printable versions of the 2016 immunization schedules for persons aged 0 through 18 years in several formats (e.g., portrait, landscape, and pocket-sized versions) and ordering instructions for laminated versions and “parent-friendly” schedules are available at the immunization schedule website.
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2016
Annals of Internal Medicie February 02, 2016 V.164 N.3
David K. Kim, MD; Carolyn B. Bridges, MD; Kathleen H. Harriman, PhD, MPH, RN, on behalf of the Advisory Committee on Immunization Practices
From the Centers for Disease Control and Prevention, Atlanta, Georgia.
In October 2015, the Advisory Committee on Immunization Practices (ACIP) approved the Recommended Adult Immunization Schedule: United States, 2016.
This schedule summarizes ACIP recommendations for the use of vaccines routinely recommended for adults in 2 figures (Figures 1 and 2), footnotes for each vaccine, and a table that describes primary contraindications and precautions for commonly used vaccines for adults (Table).
Details on these updates and information on other vaccines recommended for adults can be found at http://www.cdc.gov/vaccines/schedules.
The full ACIP recommendations for each vaccine are not included in the schedule owing to space limitations but can be found at http://www.cdc.gov/vaccines/hcp/acip-recs/index.html.
The 2016 adult immunization schedule was reviewed and approved by the American College of Physicians, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and American College of Nurse-Midwives….
PDF (CLIC on PDF)